Development and validation of an LC-MS/MS method for Tirzepatide, a dual GIP/GLP-1 receptor agonist, in rat plasma for application to a pharmacokinetic study
What the survey data actually shows While we wait for randomized controlled trials, the best clinical evidence we have comes from an international cross-sectional survey of endometriosis patients who used GLP-1 receptor agonists
An easy way to distinguish between a second test showing higher mycotoxins being the result of improved detoxification vs an increase in toxicity is what the patient response is
Fatty liver disease: Could reduce cell damage associated with fatty liver disease
Acknowledgments The authors gratefully acknowledge the contributions of researchers in the field of MASLD and carnitine metabolism, whose foundational work has informed this study
That muscle loss is one of the main reasons why up to 80 percent of people regain all the weight they lost, and often more, within one year of stopping their GLP-1 medication